|Bid||151.24 x 200|
|Ask||156.05 x 100|
|Day's Range||154.62 - 156.04|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||14.76|
|Dividend & Yield||4.60 (3.01%)|
|1y Target Est||N/A|
Harpoon Therapeutics Inc. has snared $45 million to develop a prostate cancer therapy that builds on the pioneering immuno-oncology research of co-founder Patrick Baeuerle.
here is a list of 5 undervalued stocks (no particular order) courtesy of MarketTerminal.com
In 2016, Amgen’s (AMGN) Neulasta generated revenues close to $4.6 billion, which was a slight drop from its 2015 net sales of ~$4.7 billion.